vs
Side-by-side financial comparison of HCI Group, Inc. (HCI) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
HCI Group, Inc. is the larger business by last-quarter revenue ($246.2M vs $164.7M, roughly 1.5× PTC THERAPEUTICS, INC.). HCI Group, Inc. runs the higher net margin — 39.7% vs -82.0%, a 121.6% gap on every dollar of revenue. On growth, HCI Group, Inc. posted the faster year-over-year revenue change (52.1% vs -22.7%). HCI Group, Inc. produced more free cash flow last quarter ($440.8M vs $-36.6M). Over the past eight quarters, HCI Group, Inc.'s revenue compounded faster (9.2% CAGR vs -11.5%).
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
HCI vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.2M | $164.7M |
| Net Profit | $97.7M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | 58.5% | -43.3% |
| Net Margin | 39.7% | -82.0% |
| Revenue YoY | 52.1% | -22.7% |
| Net Profit YoY | 3679.2% | -104.8% |
| EPS (diluted) | $7.29 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.2M | $164.7M | ||
| Q3 25 | $216.3M | $211.0M | ||
| Q2 25 | $221.9M | $178.9M | ||
| Q1 25 | $216.4M | $1.2B | ||
| Q4 24 | $161.9M | $213.2M | ||
| Q3 24 | $175.3M | $196.8M | ||
| Q2 24 | $206.2M | $186.7M | ||
| Q1 24 | $206.6M | $210.1M |
| Q4 25 | $97.7M | $-135.0M | ||
| Q3 25 | $65.5M | $15.9M | ||
| Q2 25 | $66.2M | $-64.8M | ||
| Q1 25 | $69.7M | $866.6M | ||
| Q4 24 | $2.6M | $-65.9M | ||
| Q3 24 | $5.7M | $-106.7M | ||
| Q2 24 | $54.1M | $-99.2M | ||
| Q1 24 | $47.6M | $-91.6M |
| Q4 25 | 58.5% | -43.3% | ||
| Q3 25 | 41.9% | 1.4% | ||
| Q2 25 | 42.5% | -19.5% | ||
| Q1 25 | 46.4% | 82.5% | ||
| Q4 24 | 3.6% | -76.2% | ||
| Q3 24 | 8.0% | -27.7% | ||
| Q2 24 | 36.9% | -21.5% | ||
| Q1 24 | 37.5% | -21.6% |
| Q4 25 | 39.7% | -82.0% | ||
| Q3 25 | 30.3% | 7.5% | ||
| Q2 25 | 29.8% | -36.3% | ||
| Q1 25 | 32.2% | 73.7% | ||
| Q4 24 | 1.6% | -30.9% | ||
| Q3 24 | 3.2% | -54.2% | ||
| Q2 24 | 26.2% | -53.1% | ||
| Q1 24 | 23.0% | -43.6% |
| Q4 25 | $7.29 | $-1.63 | ||
| Q3 25 | $4.90 | $0.20 | ||
| Q2 25 | $5.18 | $-0.83 | ||
| Q1 25 | $5.35 | $10.04 | ||
| Q4 24 | $0.32 | $-0.85 | ||
| Q3 24 | $0.52 | $-1.39 | ||
| Q2 24 | $4.24 | $-1.29 | ||
| Q1 24 | $3.81 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.0B | $-205.3M |
| Total Assets | $2.5B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | $1.9B | ||
| Q3 25 | $987.9M | $1.7B | ||
| Q2 25 | $947.2M | $2.0B | ||
| Q1 25 | $754.5M | $2.0B | ||
| Q4 24 | $532.5M | $1.1B | ||
| Q3 24 | $518.8M | $1.0B | ||
| Q2 24 | $445.8M | $1.1B | ||
| Q1 24 | $655.4M | $884.8M |
| Q4 25 | $1.0B | $-205.3M | ||
| Q3 25 | $821.8M | $-155.8M | ||
| Q2 25 | $758.6M | $-206.5M | ||
| Q1 25 | $522.7M | $-185.8M | ||
| Q4 24 | $453.3M | $-1.1B | ||
| Q3 24 | $455.3M | $-1.1B | ||
| Q2 24 | $447.3M | $-980.2M | ||
| Q1 24 | $395.7M | $-893.9M |
| Q4 25 | $2.5B | $2.9B | ||
| Q3 25 | $2.3B | $2.6B | ||
| Q2 25 | $2.4B | $2.6B | ||
| Q1 25 | $2.3B | $2.7B | ||
| Q4 24 | $2.2B | $1.7B | ||
| Q3 24 | $2.0B | $1.8B | ||
| Q2 24 | $1.9B | $1.9B | ||
| Q1 24 | $1.8B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $444.4M | $-34.3M |
| Free Cash FlowOCF − Capex | $440.8M | $-36.6M |
| FCF MarginFCF / Revenue | 179.0% | -22.3% |
| Capex IntensityCapex / Revenue | 1.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 4.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $771.4M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $444.4M | $-34.3M | ||
| Q3 25 | $26.7M | $-66.3M | ||
| Q2 25 | $145.0M | $-58.3M | ||
| Q1 25 | $162.0M | $870.1M | ||
| Q4 24 | $331.8M | $-30.0M | ||
| Q3 24 | $104.1M | $-77.0M | ||
| Q2 24 | $-29.0M | $-71.5M | ||
| Q1 24 | $182.0M | $70.8M |
| Q4 25 | $440.8M | $-36.6M | ||
| Q3 25 | $25.9M | $-69.7M | ||
| Q2 25 | $144.5M | $-59.6M | ||
| Q1 25 | $160.3M | $868.4M | ||
| Q4 24 | $327.8M | $-33.8M | ||
| Q3 24 | $103.2M | $-77.5M | ||
| Q2 24 | $-30.1M | $-78.8M | ||
| Q1 24 | $181.0M | $61.2M |
| Q4 25 | 179.0% | -22.3% | ||
| Q3 25 | 12.0% | -33.1% | ||
| Q2 25 | 65.1% | -33.3% | ||
| Q1 25 | 74.1% | 73.8% | ||
| Q4 24 | 202.5% | -15.8% | ||
| Q3 24 | 58.9% | -39.4% | ||
| Q2 24 | -14.6% | -42.2% | ||
| Q1 24 | 87.6% | 29.1% |
| Q4 25 | 1.5% | 1.4% | ||
| Q3 25 | 0.4% | 1.6% | ||
| Q2 25 | 0.2% | 0.7% | ||
| Q1 25 | 0.8% | 0.1% | ||
| Q4 24 | 2.5% | 1.8% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 0.5% | 4.0% | ||
| Q1 24 | 0.5% | 4.6% |
| Q4 25 | 4.55× | — | ||
| Q3 25 | 0.41× | -4.17× | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 2.32× | 1.00× | ||
| Q4 24 | 128.41× | — | ||
| Q3 24 | 18.33× | — | ||
| Q2 24 | -0.54× | — | ||
| Q1 24 | 3.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
PTCT
Segment breakdown not available.
